01P.F Medpace Holdings Inc

Healthcare Biotechnology Frankfurt Exchange
598.20 EUR
Close of Nov 12, 2026
330.40 623.00
Market cap
EUR 16.7B
P/E
39.0x
P/B
31.78x
ROE
87.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 01P.F undervalued?

Graham number

The Graham number of Medpace Holdings Inc cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Medpace Holdings Inc fundamental analysis

No fundamental analysis for Medpace Holdings Inc yet.

Medpace Holdings Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Medpace Holdings Inc

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory…

Full company profile